New drug cocktail takes on tough pancreatic cancer

NCT ID NCT06182072

Recruiting now Disease control Sponsor: ProDa BioTech, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called ProAgio combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer that has spread. Some participants also get an immunotherapy drug (atezolizumab). The main goals are to find a safe dose and check for early signs that the tumors shrink or stop growing. About 46 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ProAgio (also called ACT50) combined with gemcitabine, nab-paclitaxel, and sometimes atezolizumab
What this could lead to: If it works, this could point toward a new treatment option for advanced pancreatic cancer that may help control the disease longer.
What could go wrong: This is an early Phase I/Ib trial with only 46 participants, so the main goal is safety and dosing—not proof of effectiveness. The drug may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Locations

O'Neal Comprehensive Cancer Center, University of Alabama
RECRUITING

Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.